Karen M. Cichowski
Affiliations: | Harvard University, Cambridge, MA, United States |
Area:
Cell Biology, Molecular BiologyGoogle:
"Karen Cichowski"Children
Sign in to add trainee| Cory M. Johannessen | grad student | 2008 | Harvard |
| Lauren T. McGillicuddy | grad student | 2008 | Harvard |
| Pablo E. Hollstein | grad student | 2009 | Harvard |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Min J, Zaslavsky A, Fedele G, et al. (2024) Author Correction: An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB. Nature Medicine |
| Nardi F, Perurena N, Schade AE, et al. (2023) Co-targeting a MYC-eIF4A survival axis improves the efficacy of KRAS inhibitors in lung cancer. The Journal of Clinical Investigation |
| Perurena N, Lock R, Davis RA, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Reports. Medicine. 101007 |
| Miller AL, Perurena N, Gardner A, et al. (2023) DAB2IP is a bifunctional tumor suppressor that regulates wildtype RAS and inflammatory cascades in KRAS mutant colon cancer. Cancer Research |
| Zhang Y, Guillermier C, De Raedt T, et al. (2020) Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity. Iscience. 23: 101355 |
| Guerra SL, Maertens O, Kuzmickas R, et al. (2020) A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers. Cancer Cell |
| Tian T, Lofftus S, Pan Y, et al. (2020) IL1α antagonizes IL1β and promotes adaptive immune rejection of malignant tumors. Cancer Immunology Research |
| Kim A, Lu Y, Okuno SH, et al. (2020) Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). Sarcoma. 2020: 5784876 |
| Watanabe M, Kuzmickas R, Cichowski K. (2020) Abstract P1-18-27: Developing a novel combination therapy using EZH2i for HER2+ breast cancer Cancer Research. 80 |
| Widemann BC, Lu Y, Reinke D, et al. (2019) Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma. 2019: 7656747 |